AI Summary of Peer-Reviewed Research

This page presents an AI-generated summary of a published research paper. The original authors did not write or review this article. [See full disclosure ↓]

Publishing process signals: MODERATE — reflects the venue and review process. — venue and review process.

Hypodermoclysis appears generally safe in advanced cancer

A nurse in blue scrubs and pink head covering stands beside a patient lying in a hospital bed, holding a red document or clipboard, in a clinical care facility.
Research area:MedicinePalliative careCancer

What the study found

Hypodermoclysis, a less invasive form of subcutaneous fluid administration, appears to be a feasible and generally safe hydration method for adults with advanced cancer receiving palliative or hospice care.

Why the authors say this matters

The study suggests this is relevant because clinically assisted hydration near the end of life remains controversial, with uncertainty about benefits and harms. The authors conclude that decisions should be individualized according to patient goals and symptom burden.

What the researchers tested

The researchers conducted a systematic review and meta-analysis following PRISMA 2020 guidelines. They included randomized and observational studies in adults with advanced cancer receiving palliative or hospice care, and pooled local infusion-site complications and treatment discontinuation when the data were comparable.

What worked and what didn't

Five studies met the inclusion criteria, and three were suitable for quantitative synthesis. Pooled analysis estimated that about 17% of patients experienced local infusion-site complications, but these events were mostly mild and rarely led to treatment discontinuation.

What to keep in mind

The abstract says the evidence supporting routine hydration remains limited. Randomized trials did not consistently show improvements in symptoms or survival, and the available summary does not describe additional limitations beyond the small number of studies.

Key points

  • Hypodermoclysis was found to be feasible and generally safe in advanced cancer care.
  • About 17% of patients had local infusion-site complications in the pooled analysis.
  • Most complications were mild and rarely caused treatment to be stopped.
  • Randomized trials did not consistently show symptom or survival benefits from clinically assisted hydration.
  • The authors say hydration decisions should be individualized to patient goals and symptom burden.

Disclosure

Research title:
Hypodermoclysis appears generally safe in advanced cancer
Publication date:
2026-03-07
OpenAlex record:
View
AI provenance: AI provenance information is not available for this post.